scholarly journals Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum

2012 ◽  
Vol 106 (9) ◽  
pp. 1469-1474 ◽  
Author(s):  
J H Yi ◽  
J Lee ◽  
J Lee ◽  
S H Park ◽  
J O Park ◽  
...  
1991 ◽  
Vol 14 (4) ◽  
pp. 357-358 ◽  
Author(s):  
Artur Katz ◽  
Rene C. Gansl ◽  
Sergio D. Simon ◽  
Joaquim Gama-Rodrigues ◽  
Dan Waitzberg ◽  
...  

1988 ◽  
Vol 74 (3) ◽  
pp. 313-315 ◽  
Author(s):  
Eduardo Cazap ◽  
Roberto Estevez ◽  
Mario Bruno ◽  
Daniel Levy ◽  
Carlos Algamiz ◽  
...  

Patients with locally advanced or metastatic gastric adenocarcinoma received an i.v. bolus of 4′-epi-doxorubicin, 75/mg/m2/cycle, every 21 days. Partial responses were observed in 5 of 23 evaluable patients (21.7%). Treatment was generally well tolerated and toxicity was mild. The response rate to epirubicin appears to be very similar to that reported for doxorubicin. Larger doses of epirubicin could be safely used in future studies, and further evaluation of epirubicin in phase III trials is indicated.


2019 ◽  
Vol 112 ◽  
pp. 20-28
Author(s):  
Chan Kim ◽  
Hong Jae Chon ◽  
Joo Hoon Kim ◽  
Minkyu Jung ◽  
Chung Mo Nam ◽  
...  

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 63-63
Author(s):  
Akira Miki ◽  
Kazuhiro Nishikawa ◽  
Hirokazu Noshiro ◽  
Akira Tsuburaya ◽  
Yasunori Nishida ◽  
...  

63 Background: The global, randomized, Phase III ToGA study showed that the first-line treatment of trastuzumab (T-mab) combined with capecitabine and cisplatin a survival (OS) benefit for patients (pts) with HER2-positive metastatic gastric cancer (mGC). However, there is no report concerning about the efficacy and safety of T-mab containing second-line treatment for T-mab naïve patients with HER2-positive mGC. Therefore, we planned a phase II study of paclitaxel plus trastuzumab in this setting. Methods: JFMC45-1102 is multicentre Phase II study. Patient (pts) with HER2 positive (IHC3+ or IHC2+/FISH+), histologically confirmed gastric adenocarcinoma, age≥20, received one or more prior chemotherapy but no prior therapy with T-mab, normal left ventricular ejection fraction (LVEF ≥ 50%) were eligible. Pts received paclitaxel (80 mg/m2on days 1, 8, and, 15 q4w) plus T-mab (8 mg/kg for the initial dose, followed by 6 mg/kg q3w) until disease progression, unacceptable toxicity or patient’s refusal. The primary endpoint was overall response rate evaluated according to RECIST ver1.0 (ORR; Threshold and expected ORR would be 15% and 30%), and the secondary endpoints include progression free survival (PFS), time to treatment failure (TTF), overall survival (OS) and safety. A LVEF assessment was repeated every three months. Results: Between November 2011 to March 2012, 45 pts were enrolled. Pts characteristics were: gender (M/F); 36/9, median age; 69, ECOG PS0/1/2; 34/10/1, advanced/recurrence; 25/20, number of prior treatment (1/2): 40/5. At 16 weeks, 43 pts were ORR and disease control rate (CR+PR+SD) were 37.2% (95% CI; 23.0%-53.3%) and 83.7%(95% CI; 69.3%-93.2%), respectively. The LVEF assessment was performed in 31 patients. More than 10% decrease in LVEF was observed in only one patient, although total incidence of decrease in LVEF was 56% (17/31 pts). Conclusions: Combination chemotherapy of paclitaxel plus trastuzumab is generally well tolerated and showed promising activity for T-mab native patients with HER2-positive previously treated advanced or recurrent gastric cancer. Clinical trial information: UMIN000006223.


2013 ◽  
Vol 17 (4) ◽  
pp. 711-717 ◽  
Author(s):  
Gianluca Tomasello ◽  
Wanda Liguigli ◽  
Rossana Poli ◽  
Silvia Lazzarelli ◽  
Matteo Brighenti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document